Good morning, fellow humans. Erin Brodwin here, filling in for Ed Silverman. My unofficial mascot, a 25-pound pup named Dax, has fallen asleep to the sound of my typing as I sip away at my usual cup of Bolivian Fair Trade Certified coffee. The only flavored coffee I’ve ever tried is hazelnut, and one taste of that saccharin brew was enough to pull me back to the regular stuff. Here’s hoping your day is neither bitter nor overly sweet. On to the day’s news. …
A U.S. judge in the Purdue Pharma bankruptcy case plans to rule on the company’s request to approve its opioid settlement by week’s end, Reuters reports. The judge, New York-based Robert Drain, said he expected to make a ruling on Friday as to whether to approve Purdue’s request for a settlement related to its sale of opioids. The OxyContin maker claims the deal is worth more than $10 billion and has pledged $4.5 billion in exchange for legal protections against opioid-related lawsuits.
Eli Lilly (LLY) is partnering with Lycia Therapeutics to identify and develop new drugs that target disease-causing proteins, BioPharma Dive writes. As part of a collaboration announced Wednesday, Lilly will use Lycia’s LYTAC technology to develop treatments in areas including immunology and pain. Lilly will pay $35 million up front as part of the deal and up to $1.6 billion depending on Lycia’s achievement of certain development and commercial milestones.
Create a display name to comment
This name will appear with your comment